Showing 1641-1650 of 2320 results for "".
- In Phase 2b Trial, Spesolimab Meets Endpoints for Prevention of Generalized Pustular Psoriasis (GPP) Flareshttps://practicaldermatology.com/news/in-phase-2b-trial-spesolimab-meets-endpoints-for-prevention-of-generalized-pustular-psoriasis-gpp-flares/2461529/Spesolimab (Boehringer Ingelheim), an anti-interleukin-36 receptor antibody, met its primary and key secondary endpoint, demonstrating it can prevent flares in patients with generalized pustular psoriasis (GPP) and provide sustained symptom management up to 48 weeks, according to results of the P
- Amazon Launches $5-a-Month Subscription Service for Generic Drugshttps://practicaldermatology.com/news/amazon-launches-5-a-month-subscription-service-for-generic-drugs-1/2461518/In its latest move into the healthcare and pharmacy business, Amazon announced the launch of RxPass, a new benefit for Prime members that offers patients access to commonly prescribed generic medications that treat more than 80 heal
- Allergan Aesthetics Rolls Out Juvéderm Volux XChttps://practicaldermatology.com/news/allergan-aesthetics-rolls-out-juvederm-volux-xc/2461507/Allergan Aesthetics' Juvéderm Volux XC is now available at aesthetic practices nationwide. The filler is approved for patients older than 21 with moderate to severe loss of jawline definition. "With 40% of aesthetically-aware consumers considering tre
- Journey Medical Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosaceahttps://practicaldermatology.com/news/journey-medical-completes-enrollment-in-phase-3-clinical-trials-evaluating-dfd-29-for-the-treatment-of-papulopustular-rosacea/2461506/Journey Medical Corp. announced that it has fully enrolled and randomized all of the patients in its Phase 3 clinical program to assess the safety, efficacy and tolerability of DFD-29 (minocycline modified release capsules 40 mg) for the treatment of papulopustular rosacea, the company announced
- Hydrafacial Improves Acne Skin Concerns: Studyhttps://practicaldermatology.com/news/hydrafacial-improves-acne-skin-concerns-study/2461501/Hydrafacial improves acne skin concerns, according to a new study published in the Journal of Clinical and Aesthetic Dermatology (JCAD). Fully 100 percent of study participants reported clearer, less inflamed skin after a series of treatments with Hydrafacial’s pate
- Dr. B Expands Telehealth Service into Dermatologyhttps://practicaldermatology.com/news/dr-b-expands-telehealth-service-into-dermatology/2461498/Telehealth service Dr. B added several specialties to it service network, including dermatology. The move allows patients to access low or no-cost virtual doctor consultations for a variety of conditions from home. Dr. B’s online consultation fee is $15 for paying p
- New Guidance Issued on Treating Metastatic Melanoma During COVID-19https://practicaldermatology.com/news/new-guidance-issued-on-treating-metastatic-melanoma-during-covid-19/2461497/Metastatic melanoma patients taking systemic therapy should stay on treatment whenever possible, even during Covid-19 pandemic. This is the main takeaway from new research paper in Oncotarget's
- Regenerative Medicine in Action: Scars Faded Using Transplanted Hair Follicleshttps://practicaldermatology.com/news/regenerative-medicine-in-action-scars-faded-using-transplanted-hair-follicles/2461486/Skin scars began to behave more like uninjured skin after they were treated with hair follicle transplants in a small new study. The scarred skin harboured new cells and blood vessels, remodelled collagen to restore healthy patterns, and even expressed genes found in healthy unscarred s
- Acelyrin Inc. to Accelerate Development of Izokibep in HShttps://practicaldermatology.com/news/acelyrin-incs-to-accelerate-development-of-izokibep-in-hs/2461484/Acelyrin Inc’s Izokibep achieved higher orders of Hidradenitis Suppurativa Clinical Responses (HiSCR) in open label Part A of a Phase 2b/3 trial. Izokibep has been administered to over 300 patients, some for up to three years. It is a small therapeutic protein inhibitor
- Current Depression, Systemic Inflammation Linked in Psoriasishttps://practicaldermatology.com/news/current-depression-systemic-inflammation-linked-in-psoriasis/2461482/Current depression travels with increased neutrophils in psoriasis patients, especially females, finds research in the Journal of Investigative Dermatology. For the study, re